Gepant treAtments: EffectIveNess and tolERability (GAINER)
Recruiting · NCT05903027 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Florence
View the official record on ClinicalTrials.gov →Interventions studied
Rimegepant 75 MG Disintegrating Oral Tablet
What this trial is about
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III).
- At least 3 MMDs
- Good compliance to study procedures
- Availability of headache diary at least of the preceding months before enrollment
Exclusion criteria
- Subjects with contraindications for use of gepants;
- Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
- medical comorbidities that could interfere with study results;
- Pregnancy and breastfeeding.
Where it is running
2 locations listed.
- SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi - Florence, Italy
- IRCCS National Neurological Institute "C. Mondino" Foundation - Pavia, Italy